Cosmetic cross-reference

Macrogol

CAS 25322-68-3

Macrogol (CAS 25322-68-3) is a pharmaceutical compound with 0 bioactivity targets and 12,812 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
12,812
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE DrugCentral 055904D152D6

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Macrogol
CAS Number
25322-68-3
UNII
G2M7P15E5P
ChEMBL ID
CHEMBL1201478
DrugCentral Struct ID
4253
Source Match
DrugCentral (CAS), FDA GSRS (UNII)
Synonyms and normalized names
PEG-75polyethylene glycol 3350
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Constipation 1485 655.544 10010774
Macular degeneration 301 354.722 10025409
Infective pulmonary exacerbation of cystic fibrosis 230 350.375 10070608
Contraindicated product administered 16 294.261 10078504
Febrile neutropenia 895 283.98 10016288
Synovitis 8 254.049 10042868
Pemphigus 6 250.043 10034280
Systemic lupus erythematosus 22 235.119 10042945
Treatment failure 43 227.363 10066901
Appendicolith 140 219.754 10074458
Hand deformity 6 214.648 10061194
Rheumatoid arthritis 78 209.129 10039073
Abdominal pain 1181 202.03 10000081
Drug ineffective 1260 195.27 10013709
Abdominal distension 520 185.803 10000060
Maternal exposure during pregnancy 50 179.043 10071408
Completed suicide 52 176.19 10010144
Arthropathy 84 167.483 10003285
Glossodynia 36 162.931 10018388
Aplastic anaemia 163 162.774 10002967
Urinary tract infection 891 158.378 10046571
Drug intolerance 178 156.769 10061822
Appendicitis 165 138.391 10003011
Therapeutic product effect decreased 78 136.77 10082201
Pericarditis 23 136.674 10034484
Joint swelling 214 131.369 10023232
Dehydration 757 130.205 10012174
Sepsis 822 128.083 10040047
Hyponatraemia 554 122.621 10021036
Alopecia 206 121.576 10001760
Plasma cell myeloma 293 119.379 10035226
Wound 56 118.534 10052428
Exposure during pregnancy 47 117.82 10073513
Chronic sinusitis 122 109.397 10009137
Fall 1238 109.004 10016173
Toxicity to various agents 304 101.579 10070863
Blood calcium decreased 181 100.025 10005395
Drug interaction 305 99.626 10013710
Helicobacter infection 13 98.202 10054263
Arthralgia 620 97.132 10003239
Nausea 2199 97.026 10028813
Discomfort 77 95.264 10013082
Psoriatic arthropathy 20 94.499 10037162
Hypersensitivity 228 93.55 10020751
Foetal exposure during pregnancy 22 90.769 10071404
Folliculitis 5 90.428 10016936
Blood phosphorus increased 91 88.356 10050196
Sedation complication 112 87.876 10079741
Creatinine renal clearance decreased 124 87.119 10011372
Mental status changes 260 86.916 10048294

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 6 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
PEG-75 221147 SU MTHSPL
polyethylene glycol 3350 221147 SU MTHSPL
Polyethylene Glycol 3350 221147 SU MTHSPL
POLYETHYLENE GLYCOL 3350 221147 SU MTHSPL
Polyethylene glycol 3350 221147 SU MTHSPL
macrogol 8516 SY RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Macrogol used for in pharmaceutical contexts?

Macrogol (CAS 25322-68-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Macrogol?

Macrogol has 12,812 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Constipation, Macular degeneration, Infective pulmonary exacerbation of cystic fibrosis, Contraindicated product administered, Febrile neutropenia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Macrogol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for PEG-200 with EU status "permitted".

What clinical phase is Macrogol in?

No phase 1-4 clinical development badge is rendered for Macrogol because the matched compound identifier rows do not contain a max-phase value.